• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Food & Drug Administration (FDA)

Intersect ENT seeks FDA nod for Resolve steroid-releasing implant

March 8, 2017 By Sarah Faulkner

Intersect ENT

Intersect ENT (NSDQ:XENT) said today that it submitted a New Drug Application to the FDA for its Resolve steroid-releasing implant to treat chronic sinusitis patients with recurrent sinus obstruction. The Menlo Park, Calif.-based company’s implant can be placed during a routine physician office visit and is designed to be a less invasive treatment option for recurrent […]

Filed Under: Featured, Food & Drug Administration (FDA), Implants, Otolaryngology Ear, Nose & Throat, Regulatory/Compliance, Wall Street Beat Tagged With: Intersect ENT Inc.

EnGeneIC wins orphan drug designation for targeted nanocells

March 2, 2017 By Sarah Faulkner

EnGeneIC said today that the FDA granted orphan drug designation to the company’s targeted EDV nanocells for the treatment of glioblastoma multiforme. The clinical stage biopharmaceutical company is developing bacterially-derived EDV nanocells as a nanoparticle, siRNA and miRNA delivery platform designed to target and kill tumor cells, while triggering the immune system’s natural anti-tumor response. […]

Filed Under: Featured, Food & Drug Administration (FDA), Nanoparticles, Oncology, Regulatory/Compliance Tagged With: EnGeneIC

Aerie resubmits NDA for Rhopressa eye drops

March 1, 2017 By Sarah Faulkner

Aerie

Aerie Pharmaceuticals (NSDQ:AERI) said today that it resubmit a New Drug Application for the company’s Rhopressa eye drops. The Irvine, Calif.-based company’s NDA was withdrawn in October last year, after a contract manufacturer was not prepared for its pre-approval inspection. Aerie’s Rhopressa eye drops specifically target the eye’s trabecular network – the diseased tissue responsible for […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance, Wall Street Beat Tagged With: Aerie Pharmaceuticals

Trump calls for speedier approval process, while Sanders takes aim at drug prices

March 1, 2017 By Sarah Faulkner

Capitol Hill

In his 1st address to Congress, President Donald Trump called for speeding up drug approvals within the FDA. Earlier that day, Sen. Bernie Sanders (I-Vermont) proposed a bill to allow the importation of prescription drugs from Canada in the hopes of lowering drug prices. The new administration has been critical of drug prices, with Trump saying that […]

Filed Under: Featured, Food & Drug Administration (FDA), Policy, Wall Street Beat Tagged With: Capitol Hill

FDA asks Titan for more info before clinical trial of ropinirole implant

February 28, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) said today that the FDA put a hold on the clinical trial of its ropinirole implant and told the company to submit more information to the federal watchdog. After it completed an initial review of the implant’s Investigational New Drug application, the FDA asked Titan for final release test data on its ropinirole […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Neurological, Wall Street Beat Tagged With: Titan Pharmaceuticals

OncoSec wins fast track designation for electroporation combo therapy

February 27, 2017 By Sarah Faulkner

OncoSec Medical

OncoSec Medical (NSDQ:ONCS) said today that it won Fast Track Designation from the FDA for its ImmunoPulse IL-12 electroporation gene therapy for the treatment of metastatic melanoma. The biotech company’s electroporation device is designed to locally deliver DNA-based interleukin-12 to stimulate the immune system and fight off cancer cells. The ImmunoPulse device delivers a sequence […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Oncology, Regulatory/Compliance, Wall Street Beat Tagged With: OncoSec Medical

FDA accepts AcelRx’s NDA for Dsuvia pain reliever

February 27, 2017 By Sarah Faulkner

AcelRx Pharmaceuticals

AcelRx Pharmaceuticals (NSDQ:ACRX) said today that the FDA accepted the company’s New Drug Application for its Dsuvia pain relief therapy. The federal watchdog set a target decision date for October 12 this year. The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator to patients with moderate-to-severe […]

Filed Under: Featured, Food & Drug Administration (FDA), Pain Management, Regulatory/Compliance, Sublingual films Tagged With: AcelRx

Intersect ENT wins FDA nod for Propel Contour steroid-releasing implant

February 24, 2017 By Sarah Faulkner

Intersect ENT (NSDQ:XENT) said today that it won FDA approval for its Propel Contour steroid-releasing implant for the treatment of chronic sinusitis in the frontal and maxillary sinsuses. The Menlo Park, Calif.-based company’s portfolio of steroid-releasing implants are used in patients undergoing ethmoid, frontal or maxillary surgeries to treat chronic sinusitis. “The approval of Propel […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Regulatory/Compliance, Wall Street Beat Tagged With: Intersect ENT Inc.

FDA accepts Ocular’s NDA resubmission for Dextenza

February 22, 2017 By Sarah Faulkner

Ocular Therapeutix

Ocular Therapeutix (NSDQ:OCUL) said today that the FDA accepted the company’s resubmitted New Drug Application for its post-surgical ocular pain reliever, Dextenza. The hydrogel plug, inserted into a patient’s tear duct, is designed to deliver a sustained dose of dexamethasone over 4 weeks following opthalmic surgery. The Bedford, Mass.-based company has had trouble gaining regulatory approval […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Hydrogels, Optical/Ophthalmic, Regulatory/Compliance, Wall Street Beat Tagged With: Ocular Therapeutix

Titan Pharmaceutical’s match-sized implant fights back against opioid addiction

February 14, 2017 By Sarah Faulkner

Titan Pharmaceuticals

The ongoing opioid crisis in the U.S. is harrowing – 91 Americans die every day from an opioid overdose, according to the Centers for Disease Control & Prevention. Companies are searching for innovative ways to deliver opioid maintenance treatment to patients that are hoping to get clean. Buprenorphine is a compound used for medication-assisted treatment, traditionally administered […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Wall Street Beat Tagged With: Centers for Disease Control & Prevention, Massachusetts Institute of Technology, Titan Pharmaceuticals

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 89
  • Page 90
  • Page 91
  • Page 92
  • Page 93
  • Interim pages omitted …
  • Page 99
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS